BC-7013

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C29H40O5S
Molecular Weight	500.69
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12C(=O)CC[C@]13CC[C@@H](C)[C@@]2(C)[C@@H](C[C@@](C)(C=C)[C@@H](O)[C@@H]3C)OC(=O)CSC4=CC=CC(CO)=C4

InChI

InChIKey=KELRBTWVTDHIHS-KGTFJIFRSA-N

InChI=1S/C29H40O5S/c1-6-27(4)15-23(34-24(32)17-35-21-9-7-8-20(14-21)16-30)28(5)18(2)10-12-29(19(3)26(27)33)13-11-22(31)25(28)29/h6-9,14,18-19,23,25-26,30,33H,1,10-13,15-17H2,2-5H3/t18-,19+,23-,25+,26+,27-,28+,29+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C29H40O5S
Molecular Weight	500.69
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	8 / 8
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:48:58 GMT 2023` Edited by `admin` on `Sat Dec 16 11:48:58 GMT 2023`
Record UNII	548N5X8LTS
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BC-7013

Common Name

English

BC 7013

Code

English

14-O-((3-HYDROXYMETHYLPHENYLSULFANYL)ACETYL)MUTILIN

Systematic Name

English

ACETIC ACID, 2-((3-(HYDROXYMETHYL)PHENYL)THIO)-, (3AS,4R,5S,6S,8R,9R,9AR,10R)-6-ETHENYLDECAHYDRO-5-HYDROXY-4,6,9,10-TETRAMETHYL-1-OXO-3A,9-PROPANO-3AH-CYCLOPENTACYCLOOCTEN-8-YL ESTER

Systematic Name

English

14-O-[(3-Hydroxymethylphenylsulfanyl)acetyl]mutilin

Common Name

English

(3aS,4R,5S,6S,8R,9R,9aR,10R)-6-Ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl 2-[[3-(hydroxymethyl)phenyl]thio]acetate

Systematic Name

English

Code System Code Type Description

FDA UNII

548N5X8LTS

Created by admin on Sat Dec 16 11:48:58 GMT 2023 , Edited by admin on Sat Dec 16 11:48:58 GMT 2023

PRIMARY

MANUFACTURER PRODUCT INFORMATION

BC-7013

Created by admin on Sat Dec 16 11:48:58 GMT 2023 , Edited by admin on Sat Dec 16 11:48:58 GMT 2023

PRIMARY

Pleuromutilins were discovered as natural-product antibiotics in 1950. Tiamulin was the first pleuromutilin compound to be approved for veterinary use in 1979, followed by valnemulin in 1999.Most pleuromutilins have an antibacterial spectrum that spans the common pathogens involved in both skin and respiratory tract infections. Two new pleuromutilins, BC-3205 and BC-7013 (both Nabriva Therapeutics AG), have entered clinical trials. In this review, the key properties of pleuromutilin derivatives, designed primarily through modifications at the C(14) side chain, are presented, and the potential of these compounds in systemic therapy in humans is discussed. BC7013 belongs to a series of proprietary Nabriva pleuromutilins, which have been designed by Nabrivas medicinal chemists to fulfill the specific requirements of a topical antibacterial agent. The clinical study is designed to evaluate safety and tolerability of BC7013.

PUBCHEM

16656782

Created by admin on Sat Dec 16 11:48:58 GMT 2023 , Edited by admin on Sat Dec 16 11:48:58 GMT 2023

PRIMARY

CAS

1028291-66-8

Created by admin on Sat Dec 16 11:48:58 GMT 2023 , Edited by admin on Sat Dec 16 11:48:58 GMT 2023

PRIMARY

Related Record Type Details


					548N5X8LTS

BC-7013

ACTIVE MOIETY

Comments:

Conclusions: BC-7013 exhibited potent antimicrobial activity against the most prevalent Gram-positive pathogens involved in uSSSI, being more active against staphylococci than antimicrobials currently available and inhibited growth of 100% of S. aureus at an MIC 0.03 .MU.g/ml, including MRSA. BC-7013 was highly active against Staphylococcus spp., including MRSA and CA-MRSA, and BC-7013 inhibited 100.0% of S. aureus at an MIC value 0.03 .MU.g/ml. The overall potency of BC-7013 (MIC90 of 0.03 0.06 .MU.g/ml) against S. aureus and CoNS was 4- to 8-fold greater than retapamulin and was more active than the other tested agents. BC-7013 also exhibited potent activity against group A (MIC90 of 0.03 .MU.g/ml) and group B (MIC90, 0.06 .MU.g/ml) streptococci, being the next most common cause of uSSSI.

Amount: